Miltefosine represses HIV-1 replication in human dendritic cell/T-cell cocultures partially by inducing secretion of type-I interferon

Virology

Volumn 432, Issue 2, 2012, Pages 271-276

  Garg, Ravendra ^a   Tremblay, Michel J ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

AIDS; HIV 1; Miltefosine; T cells and dendritic cells

Indexed keywords

INTERFERON; INTERFERON RECEPTOR; MILTEFOSINE;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; COCULTURE TECHNIQUES; DENDRITIC CELLS; HIV-1; HUMANS; INTERFERON TYPE I; PHOSPHORYLCHOLINE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; PROTOZOA; VACCINIA VIRUS;

EID: 84865285388     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.05.032     Document Type: Article

References (38)

1. + T-cell lines by distinct mechanisms: evidence for decreased stability and aberrant processing of HIV-1 proteins. Virology 1995, 214(2):379-386.
2. Alcami A., Symons J.A., Smith G.L. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol. 2000, 74(23):11230-11239.
3. Alvar J., Aparicio P., Aseffa A., Den Boer M., Canavate C., Dedet J.-P., Gradoni L., Ter Horst R., Lopez-Velez R., Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 2008, 21(2):334-359.
4. Alvar J., Canavate C., Gutierrez-Solar B., Jimenez M., Laguna F., Lopez-Velez R., Molina R., Moreno J. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 1997, 10(2):298-319.
5. Baca-Regen L., Heinzinger N., Stevenson M., Gendelman H.E. Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes. J. Virol. 1994, 68(11):7559-7565.
6. Beckers T., Voegeli R., Hilgard P. Molecular and cellular effects of hexadecylphosphocholine (Miltefosine) in human myeloid leukaemic cell lines. Eur. J. Cancer 1994, 30A(14):2143-2150.
7. Blaha C., Duchĉne M., Aspöck H., Walochnik J. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis. J. Antimicrob. Chemother. 2006, 57(2):273-278.
8. Bounou S., Leclerc J.E., Tremblay M.J. Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J. Virol. 2002, 76(3):1004-1014.
9. Chugh P., Bradel-Tretheway B., Monteiro-Filho C.M., Planelles V., Maggirwar S.B., Dewhurst S., Kim B. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology 2008, 5:11.
10. Coccia E.M., Krust B., Hovanessian A.G. Specific inhibition of viral protein synthesis in HIV-infected cells in response to interferon treatment. J. Biol. Chem. 1994, 269(37):23087-23094.
11. Coleman C.M., Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 2009, 6:51.
12. Croft S.L., Neal R.A., Pendergast W., Chan J.H. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 1987, 36(16):2633-2636.
13. Dornadula G., Zhang H., Shetty S., Pomerantz R.J. HIV-1 virions produced from replicating peripheral blood lymphocytes are more infectious than those from nonproliferating macrophages due to higher levels of intravirion reverse transcripts: implications for pathogenesis and transmission. Virology 1999, 253(1):10-16.
14. Eue I. Hexadecylphosphocholine selectively upregulates expression of intracellular adhesion molecule-1 and class I major histocompatibility complex antigen in human monocytes. J. Exp. Ther. Oncol. 2002, 2(6):333-336.
15. + T lymphocytes. J. Immunol. 2007, 178(5):2862-2871.
16. Hochhuth C.H., Vehmeyer K., Eibl H., Unger C. Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell. Immunol. 1992, 141(1):161-168.
17. Jha T.K., Sundar S., Thakur C.P., Bachmann P., Karbwang J., Fischer C., Voss A., Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral Leishmaniasis. N. Engl. J. Med. 1999, 341(24):1795-1800.
18. Le Fichoux Y., Rousseau D., Ferrua B., Ruette S., Lelievre A., Grousson D., Kubar J. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob. Agents Chemother. 1998, 42(3):654-658.
19. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106(3):255-258.
20. Murray H.W., Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. 2000, 181(2):795-799.
21. Pion M., Arrighi J.F., Jiang J., Lundquist C.A., Hartley O., Aiken C., Piguet V. Analysis of HIV-1-X4 fusion with immature dendritic cells identifies a specific restriction that is independent of CXCR4 levels. J. Invest. Dermatol. 2007, 127(2):319-323.
22. Ramirez-Pineda J.R., Frohlich A., Berberich C., Moll H. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J. Immunol. 2004, 172(10):6281-6289.
23. Rihl M., Stoll M., Ulbricht K., Bange F.C., Schmidt R.E. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J. Infect. 2006, 53(1):e25-e27.
24. Saraiva V.B., Gibaldi D., Previato J.O., Mendonca-Previato L., Bozza M.T., Freire-de-Lima C.G., Heise N. Proinflammatory and cytotoxic effects of hexadecylphosphocholine (Miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob. Agents Chemother. 2002, 46(11):3472-3477.
25. Schraner C., Hasse B., Hasse U., Baumann D., Faeh A., Burg G., Grimm F., Mathis A., Weber R., Gunthard H.F. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin. Infect. Dis. 2005, 40(12):e120-e124.
26. Shirazi Y., Pitha P.M. Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J. Virol. 1992, 66(3):1321-1328.
27. Sindermann H., Engel K.R., Fischer C., Bommer W. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis. 2004, 39(10):1520-1523. M.C.U. Program.
28. Sundar S., Rosenkaimer F., Makharia M.K., Goyal A.K., Mandal A.K., Voss A., Hilgard P., Murray H.W. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998, 352(9143):1821-1823.
29. Symons J.A., Alcamí A., Smith G.L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species soecificity. Cell 1995, 81(4):551-560.
30. Tremblay M., Olivier M., Bernier R. Leishmania and the pathogenesis of HIV infection. Parasitol. Today 1996, 12(7):257-261.
31. Trudel N., Garg R., Messier N., Sundar S., Ouellette M., Tremblay M.J. Intracellular survival of leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J. Infect. Dis. 2008, 198(9):1292-1299.
32. Valdivieso E., Rangel A., Moreno J., Saugar J.M., Cañavate C., Alvar J., Dagger F. Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp. Exp. Parasitol. 2010, 126(4):557-563.
33. Wadhone P., Maiti M., Agarwal R., Kamat V., Martin S., Saha B. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. J. Immunol. 2009, 182(11):7146-7154.
34. White R.E., Powell D.J., Berry C. HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites. FASEB J. 2011, 25(5):1729-1736.
35. Widmer F., Wright L.C., Obando D., Handke R., Ganendren R., Ellis D.H., Sorrell T.C. Hexadecylphosphocholine (Miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob. Agents Chemother. 2006, 50(2):414-421.
36. Wolday D., Berhe N., Akuffo H., Britton S. Leishmania-HIV interaction: immunopathogenic mechanisms. Parasitol. Today 1999, 15(5):182-187.
37. Wu L., KewalRamani V.N. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 2006, 6(11):859-868.
38. Zeisig R., Rudolf M., Eue I., Arndt D. Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J. Cancer Res. Clin. Oncol. 1995, 121(2):69-75.